AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

AstraZeneca is set to acquire biotechnology firm EsoBiotec for up to $1 billion, including a $425 million upfront payment and ...

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

AstraZeneca to buy in vivo cell therapy company, EsoBiotec for US$ 1billion: Cambridge, UK Tuesday, March 18, 2025, 10:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceu ...

In addition, AstraZeneca has invested $300 million in its Maryland facility to support the development of cell therapies. EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform speeds up gene ...

The UK drugmaker AstraZeneca has agreed to acquire Belgian cell therapy developer EsoBiotec for up to $1bn to enhance its cancer treatment capabilities. Read more.